sodium channel modulator

Mechanism

Related News

FDA Grants Priority Review to Relutrigine for Rare Epileptic Encephalopathies

Mar 31, 2026

The FDA has granted Priority Review to relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target date of September 2026. Phase 2/3 trial data showed a 53% placebo-adjusted reduction in motor seizures and 66.2% increase in seizure-free days. If approved, it would be the first targeted therapy for these rare, fatal childhood conditions.

Praxis Submits Two NDAs to FDA, Reports $926M Cash Position and $303M Net Loss

Feb 19, 2026

Praxis Precision Medicines submitted NDAs for ulixacaltamide and relutrigine to the FDA, reported cash and investments of $926 million as of December 31, 2025, and disclosed a net loss of $303.3 million for full-year 2025.

Praxis Precision Medicines Submits Two NDAs, Reports $926M Cash Position

Dec 30, 2025

Praxis Precision Medicines has submitted new drug applications for ulixacaltamide in essential tremor and relutrigine in rare epilepsies, both granted Breakthrough Therapy Designation. The company reported $926 million in cash as of December 31, 2025.